NB Capital was formed in 2001 by a small group of financial investors and a major US based hedge fund. Since the beginning NB Capital has been focused on investing capital in public and private equity markets using principles of Risk aversion.

The current investor base is globally spread institutional, SWFs and family offices. Discretionary capital approximates 550 mio. USD. Focus has been on all phases of pharmaceutical drug development and commercial enterprise, a global 2,5 trillion USD plus market cap sector.

Almost every institutional investor is exposed to this sector, yet it remains one of the most complex , treacherous and yet rewarding sectors of them all. The investment experience of more than 21 years by our Chief Investment Officer and a multifaceted expert team aims at finding the rare opportunities that add value to even the largest and most specialized investors.

For more information about NB Capital and this approach, please contact Florian Schönharting, Chief Investment Officer, +45 70201263

Disclaimer and Legal Notice
NB Capital provides this web site as a service and for informational purposes only. While we have attempted to maintain the information on this web site as accurately as possible, this information may contain errors or omissions for which we disclaim any and all liability.

You may temporarily download and store one or more of these pages for the purpose of viewing only. Any other use, including reproduction, permanent storage, or retransmission, of the contents of this web site is prohibited without the prior written consent of NB Capital.

Any dispute between you and NB Capital related to the contents of this web site shall be settled in accordance with Danish law at the competent Danish court.